Selected research
Industry Research
Oral Mesalazine Industry Research Report 2026
Market perspective
The global Oral Mesalazine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Oral Mesalazine market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Oral Mesalazine market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Oral Mesalazine market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Oral Mesalazine include Teva Pharmaceutical Industries, Ferring Global, AbbVie, Tillotts Pharma, Shire, Salix Pharmaceuticals, Nogra Pharma Limited, Morningside Healthcare and Dr. Falk Pharma UK. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Oral Mesalazine market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Oral Mesalazine.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oral Mesalazine Market by Company
Teva Pharmaceutical Industries
Ferring Global
AbbVie
Tillotts Pharma
Shire
Salix Pharmaceuticals
Nogra Pharma Limited
Morningside Healthcare
Dr. Falk Pharma UK
Oral Mesalazine Segment by Type
Capsules
Granule
Tablets
Oral Mesalazine Segment by Application
Inflammatory Bowel Disease
Ulcerative Colitis
Crohn's Disease
Others
Oral Mesalazine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Mesalazine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oral Mesalazine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Mesalazine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oral Mesalazine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Capsules
- Granule
- Tablets
Applications
- Inflammatory Bowel Disease
- Ulcerative Colitis
- Crohn's Disease
- Others
Companies covered
- Teva Pharmaceutical Industries
- Ferring Global
- AbbVie
- Tillotts Pharma
- Shire
- Salix Pharmaceuticals
- Nogra Pharma Limited
- Morningside Healthcare
- Dr. Falk Pharma UK
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Oral Mesalazine by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Capsules
- 2.2.3 Granule
- 2.2.4 Tablets
- 2.3 Oral Mesalazine by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Inflammatory Bowel Disease
- 2.3.3 Ulcerative Colitis
- 2.3.4 Crohn's Disease
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Oral Mesalazine Breakdown Data by Type
- 3.1 Global Oral Mesalazine Historic Market Size by Type (2021-2026)
- 3.2 Global Oral Mesalazine Forecasted Market Size by Type (2027-2032)
4 Oral Mesalazine Breakdown Data by Application
- 4.1 Global Oral Mesalazine Historic Market Size by Application (2021-2026)
- 4.2 Global Oral Mesalazine Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Oral Mesalazine Market Perspective (2021-2032)
- 5.2 Global Oral Mesalazine Growth Trends by Region
- 5.2.1 Global Oral Mesalazine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Oral Mesalazine Historic Market Size by Region (2021-2026)
- 5.2.3 Oral Mesalazine Forecasted Market Size by Region (2027-2032)
- 5.3 Oral Mesalazine Market Dynamics
- 5.3.1 Oral Mesalazine Industry Trends
- 5.3.2 Oral Mesalazine Market Drivers
- 5.3.3 Oral Mesalazine Market Challenges
- 5.3.4 Oral Mesalazine Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Oral Mesalazine Players by Revenue
- 6.1.1 Global Top Oral Mesalazine Players by Revenue (2021-2026)
- 6.1.2 Global Oral Mesalazine Revenue Market Share by Players (2021-2026)
- 6.2 Global Oral Mesalazine Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Oral Mesalazine Head Office and Area Served
- 6.4 Global Oral Mesalazine Players, Product Type & Application
- 6.5 Global Oral Mesalazine Manufacturers Established Date
- 6.6 Global Oral Mesalazine Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Oral Mesalazine Market Size (2021-2032)
- 7.2 North America Oral Mesalazine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Oral Mesalazine Market Size by Country (2021-2026)
- 7.4 North America Oral Mesalazine Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Oral Mesalazine Market Size (2021-2032)
- 8.2 Europe Oral Mesalazine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Oral Mesalazine Market Size by Country (2021-2026)
- 8.4 Europe Oral Mesalazine Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Oral Mesalazine Market Size (2021-2032)
- 9.2 Asia-Pacific Oral Mesalazine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Oral Mesalazine Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Oral Mesalazine Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Oral Mesalazine Market Size (2021-2032)
- 10.2 South America Oral Mesalazine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Oral Mesalazine Market Size by Country (2021-2026)
- 10.4 South America Oral Mesalazine Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Oral Mesalazine Market Size (2021-2032)
- 11.2 Middle East & Africa Oral Mesalazine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Oral Mesalazine Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Oral Mesalazine Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Teva Pharmaceutical Industries
- 12.1.1 Teva Pharmaceutical Industries Company Information
- 12.1.2 Teva Pharmaceutical Industries Business Overview
- 12.1.3 Teva Pharmaceutical Industries Revenue in Oral Mesalazine Business (2021-2026)
- 12.1.4 Teva Pharmaceutical Industries Oral Mesalazine Product Portfolio
- 12.1.5 Teva Pharmaceutical Industries Recent Developments
- 12.2 Ferring Global
- 12.2.1 Ferring Global Company Information
- 12.2.2 Ferring Global Business Overview
- 12.2.3 Ferring Global Revenue in Oral Mesalazine Business (2021-2026)
- 12.2.4 Ferring Global Oral Mesalazine Product Portfolio
- 12.2.5 Ferring Global Recent Developments
- 12.3 AbbVie
- 12.3.1 AbbVie Company Information
- 12.3.2 AbbVie Business Overview
- 12.3.3 AbbVie Revenue in Oral Mesalazine Business (2021-2026)
- 12.3.4 AbbVie Oral Mesalazine Product Portfolio
- 12.3.5 AbbVie Recent Developments
- 12.4 Tillotts Pharma
- 12.4.1 Tillotts Pharma Company Information
- 12.4.2 Tillotts Pharma Business Overview
- 12.4.3 Tillotts Pharma Revenue in Oral Mesalazine Business (2021-2026)
- 12.4.4 Tillotts Pharma Oral Mesalazine Product Portfolio
- 12.4.5 Tillotts Pharma Recent Developments
- 12.5 Shire
- 12.5.1 Shire Company Information
- 12.5.2 Shire Business Overview
- 12.5.3 Shire Revenue in Oral Mesalazine Business (2021-2026)
- 12.5.4 Shire Oral Mesalazine Product Portfolio
- 12.5.5 Shire Recent Developments
- 12.6 Salix Pharmaceuticals
- 12.6.1 Salix Pharmaceuticals Company Information
- 12.6.2 Salix Pharmaceuticals Business Overview
- 12.6.3 Salix Pharmaceuticals Revenue in Oral Mesalazine Business (2021-2026)
- 12.6.4 Salix Pharmaceuticals Oral Mesalazine Product Portfolio
- 12.6.5 Salix Pharmaceuticals Recent Developments
- 12.7 Nogra Pharma Limited
- 12.7.1 Nogra Pharma Limited Company Information
- 12.7.2 Nogra Pharma Limited Business Overview
- 12.7.3 Nogra Pharma Limited Revenue in Oral Mesalazine Business (2021-2026)
- 12.7.4 Nogra Pharma Limited Oral Mesalazine Product Portfolio
- 12.7.5 Nogra Pharma Limited Recent Developments
- 12.8 Morningside Healthcare
- 12.8.1 Morningside Healthcare Company Information
- 12.8.2 Morningside Healthcare Business Overview
- 12.8.3 Morningside Healthcare Revenue in Oral Mesalazine Business (2021-2026)
- 12.8.4 Morningside Healthcare Oral Mesalazine Product Portfolio
- 12.8.5 Morningside Healthcare Recent Developments
- 12.9 Dr. Falk Pharma UK
- 12.9.1 Dr. Falk Pharma UK Company Information
- 12.9.2 Dr. Falk Pharma UK Business Overview
- 12.9.3 Dr. Falk Pharma UK Revenue in Oral Mesalazine Business (2021-2026)
- 12.9.4 Dr. Falk Pharma UK Oral Mesalazine Product Portfolio
- 12.9.5 Dr. Falk Pharma UK Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst